Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanaMa: Panitumumab Maintenance in Metastatic Colorectal Cancer
NCT01991873Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Apr 2014
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival. Started Apr 2014; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01991873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01991873.